{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T22:14:52Z","timestamp":1777932892550,"version":"3.51.4"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"S1","license":[{"start":{"date-parts":[[2021,12,13]],"date-time":"2021-12-13T00:00:00Z","timestamp":1639353600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,12,13]],"date-time":"2021-12-13T00:00:00Z","timestamp":1639353600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100007013","name":"F. Hoffmann-La Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1007\/s40273-021-01118-2","type":"journal-article","created":{"date-parts":[[2021,12,13]],"date-time":"2021-12-13T02:02:36Z","timestamp":1639360956000},"page":"103-115","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Patient and Caregiver Treatment Preferences in Type 2 and Non-ambulatory Type 3 Spinal Muscular Atrophy: A Discrete Choice Experiment Survey in Five European Countries"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2952-150X","authenticated-orcid":false,"given":"Siu Hing","family":"Lo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5773-4599","authenticated-orcid":false,"given":"Claire","family":"Lawrence","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasmina","family":"Mart\u00ed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreia","family":"Caf\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7597-6556","authenticated-orcid":false,"given":"Andrew J.","family":"Lloyd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,12,13]]},"reference":[{"key":"1118_CR1","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/1750-1172-6-71","volume":"6","author":"A D\u2019Amico","year":"2011","unstructured":"D\u2019Amico A, Mercuri E, Tiziano FD, Bertini E. Spinal muscular atrophy. Orphanet J Rare Dis. 2011;6:71. https:\/\/doi.org\/10.1186\/1750-1172-6-71.","journal-title":"Orphanet J Rare Dis"},{"key":"1118_CR2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3389\/fmolb.2016.00007","volume":"3","author":"MER Butchbach","year":"2016","unstructured":"Butchbach MER. Copy number variations in the survival motor neuron genes: Implications for spinal muscular atrophy and other neurodegenerative diseases. Front Mol Biosci. 2016;3:7. https:\/\/doi.org\/10.3389\/fmolb.2016.00007.","journal-title":"Front Mol Biosci"},{"issue":"2","key":"1118_CR3","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.nmd.2015.10.006","volume":"26","author":"E Mercuri","year":"2016","unstructured":"Mercuri E, Finkel R, Montes J, Mazzone ES, Sormani MP, Main M, et al. Patterns of disease progression in type 2 and 3 SMA: implications for clinical trials. Neuromuscul Disord. 2016;26(2):126\u201331. https:\/\/doi.org\/10.1016\/j.nmd.2015.10.006.","journal-title":"Neuromuscul Disord"},{"issue":"9","key":"1118_CR4","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1212\/WNL.0000000000000741","volume":"83","author":"RS Finkel","year":"2014","unstructured":"Finkel RS, McDermott MP, Kaufmann P, Darras BT, Chung WK, Sproule DM, et al. Observational study of spinal muscular atrophy type I and implications for clinical trials. Neurology. 2014;83(9):810\u20137. https:\/\/doi.org\/10.1212\/WNL.0000000000000741.","journal-title":"Neurology"},{"issue":"2","key":"1118_CR5","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1002\/acn3.51281","volume":"8","author":"M Annoussamy","year":"2021","unstructured":"Annoussamy M, Seferian AM, Daron A, P\u00e9r\u00e9on Y, Cances C, Vuillerot C, et al. Natural history of Type 2 and 3 spinal muscular atrophy: 2-year NatHis-SMA study. Ann Clin Transl Neurol. 2021;8(2):359\u201373. https:\/\/doi.org\/10.1002\/acn3.51281.","journal-title":"Ann Clin Transl Neurol"},{"key":"1118_CR6","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0201004","author":"A Chabanon","year":"2018","unstructured":"Chabanon A, Seferian AM, Daron A, P\u00e9r\u00e9on Y, Cances C, Vuillerot C, et al. Prospective and longitudinal natural history study of patients with Type 2 and 3 spinal muscular atrophy: baseline data NatHis-SMA study. PLoS ONE. 2018. https:\/\/doi.org\/10.1371\/journal.pone.0201004.","journal-title":"PLoS ONE"},{"key":"1118_CR7","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1186\/s12883-015-0473-3","volume":"15","author":"Y Qian","year":"2015","unstructured":"Qian Y, McGraw S, Henne J, Jarecki J, Hobby K, Yeh WS. Understanding the experiences and needs of individuals with Spinal Muscular Atrophy and their parents: a qualitative study. BMC Neurol. 2015;15:217. https:\/\/doi.org\/10.1186\/s12883-015-0473-3.","journal-title":"BMC Neurol"},{"issue":"5","key":"1118_CR8","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.nmd.2017.01.018","volume":"27","author":"F Rouault","year":"2017","unstructured":"Rouault F, Christie-Brown V, Broekgaarden R, Gusset N, Henderson D, Marczuk P, et al. Disease impact on general well-being and therapeutic expectations of European Type II and Type III spinal muscular atrophy patients. Neuromuscul Disord. 2017;27(5):428\u201338. https:\/\/doi.org\/10.1016\/j.nmd.2017.01.018.","journal-title":"Neuromuscul Disord"},{"issue":"1","key":"1118_CR9","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s12883-017-0853-y","volume":"17","author":"S McGraw","year":"2017","unstructured":"McGraw S, Qian Y, Henne J, Jarecki J, Hobby K, Yeh WS. A qualitative study of perceptions of meaningful change in spinal muscular atrophy. BMC Neurol. 2017;17(1):68. https:\/\/doi.org\/10.1186\/s12883-017-0853-y.","journal-title":"BMC Neurol"},{"issue":"5","key":"1118_CR10","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.nmd.2021.01.012","volume":"31","author":"N Gusset","year":"2021","unstructured":"Gusset N, Stalens C, Stumpe E, Klouvi L, Mejat A, Ouillade MC, et al. Understanding European patient expectations towards current therapeutic development in spinal muscular atrophy. Neuromuscul Disord. 2021;31(5):419\u201330. https:\/\/doi.org\/10.1016\/j.nmd.2021.01.012.","journal-title":"Neuromuscul Disord"},{"key":"1118_CR11","unstructured":"European Medicines Agency. SPINRAZA Summary of product characteristics. 2021. European Medicines Agency. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/spinraza-epar-product-information_en.pdf. Accessed 16 Jun 2020"},{"issue":"2","key":"1118_CR12","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1111\/jcmm.12224","volume":"18","author":"C Zanetta","year":"2014","unstructured":"Zanetta C, Riboldi G, Nizzardo M, Simone C, Faravelli I, Bresolin N, et al. Molecular, genetic and stem cell-mediated therapeutic strategies for spinal muscular atrophy (SMA). J Cell Mol Med. 2014;18(2):187\u201396. https:\/\/doi.org\/10.1111\/jcmm.12224.","journal-title":"J Cell Mol Med"},{"key":"1118_CR13","unstructured":"European Medicines Agency. ZOLGENSMA Summary of product characteristics. European Medicines Agency. 2021. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/zolgensma-epar-product-information_en.pdf. Accessed 27 Apr 2021."},{"key":"1118_CR14","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","volume":"377","author":"JR Mendell","year":"2017","unstructured":"Mendell JR, Al-Zaidy S, Shell R, Arnold WD, Rodino-Klapac LR, Prior TW, et al. Single-dose gene-replacement therapy for spinal muscular atrophy. N Engl J Med. 2017;377:1713\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1706198.","journal-title":"N Engl J Med"},{"key":"1118_CR15","unstructured":"Strauss K, Muntoni F, Farrar M, Saito K, Mendell J, Servais L, et al. Onasemnogene Abeparvovec Gene Therapy in Presymptomatic Spinal Muscular Atrophy (SMA): SPR1NT Study Update in Children with 2 Copies of SMN2 (4190). Neurology. 2021;96."},{"key":"1118_CR16","unstructured":"Strauss K, Muntoni F, Farrar M, Saito K, Mendell J, Servais L, et al. Onasemnogene Abeparvovec Gene Therapy in Presymptomatic Spinal Muscular Atrophy (SMA): SPR1NT Study Update in Children with 3 Copies of SMN2 (4163). Neurology. 2021;96."},{"key":"1118_CR17","doi-asserted-by":"crossref","unstructured":"Darras BT, Masson R, Mazurkiewicz-Be\u0142dzi\u0144ska M, Rose K, Xiong H, Zanoteli E, et al. FIREFISH Part 2: 24-month Efficacy and Safety of Risdiplam in Infants with Type 1 Spinal Muscular Atrophy (SMA) (4126). Neurology. 2021;96.","DOI":"10.1055\/s-0041-1739636"},{"key":"1118_CR18","unstructured":"Mercuri E, Barisic N, Boespflug-Tanguy O, Day JW, Deconinck N, Kostera-Pruszczyk A, et al. SUNFISH Part 2: Efficacy and Safety Of Risdiplam (RG7916) in Patients with Type 2 or Non-ambulant Type 3 Spinal Muscular Atrophy (SMA) (1260). Neurology. 2020;96."},{"key":"1118_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2020.04.1314","author":"SH Lo","year":"2020","unstructured":"Lo SH, Paracha N, Gorni K, Lloyd A. PRO93 do caregivers and patients value the avoidance of lumbar punctures in spinal muscular atrophy? A stated preference survey. Value Heal. 2020. https:\/\/doi.org\/10.1016\/j.jval.2020.04.1314.","journal-title":"Value Heal."},{"key":"1118_CR20","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s13023-020-01667-3","volume":"16","author":"A Monnette","year":"2021","unstructured":"Monnette A, Chen E, Hong D, Bazzano A, Dixon S, Arnold WD, et al. Treatment preference among patients with spinal muscular atrophy (SMA): a discrete choice experiment. Orphanet J Rare Dis. 2021;16:36. https:\/\/doi.org\/10.1186\/s13023-020-01667-3.","journal-title":"Orphanet J Rare Dis"},{"issue":"4","key":"1118_CR21","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.jval.2016.04.004","volume":"19","author":"AB Hauber","year":"2016","unstructured":"Hauber AB, Gonz\u00e1lez JM, Groothuis-Oudshoorn CGM, Prior T, Marshall DA, Cunningham C, et al. Statistical methods for the analysis of discrete choice experiments: a report of the ISPOR conjoint analysis good research practices task force. Value Health. 2016;19(4):300\u201315. https:\/\/doi.org\/10.1016\/j.jval.2016.04.004.","journal-title":"Value Health."},{"key":"1118_CR22","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jval.2012.08.2223","volume":"16","author":"FR Johnson","year":"2013","unstructured":"Johnson FR, Lancsar E, Marshall D, Kilambi V, M\u00fchlbacher A, Regier DA, et al. Constructing experimental designs for discrete-choice experiments: report of the ISPOR conjoint analysis experimental design good research practices task force. Value Health. 2013;16:3\u201313. https:\/\/doi.org\/10.1016\/j.jval.2012.08.2223.","journal-title":"Value Health."},{"issue":"2","key":"1118_CR23","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1002\/hec.1697","volume":"21","author":"EW De Bekker-Grob","year":"2012","unstructured":"De Bekker-Grob EW, Ryan M, Gerard K. Discrete choice experiments in health economics: a review of the literature. Health Econ. 2012;21(2):145\u201372. https:\/\/doi.org\/10.1002\/hec.1697.","journal-title":"Health Econ"},{"key":"1118_CR24","unstructured":"U.S. Food and Drug Administration. Approval Package for Spinraza Injection, 2.4 mg\/mL. 2016. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2016\/209531Orig1s000Approv.pdf. Accessed 27 Apr 2021."},{"issue":"7","key":"1118_CR25","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1056\/NEJMoa1710504","volume":"378","author":"E Mercuri","year":"2018","unstructured":"Mercuri E, Darras BT, Chiriboga CA, Day JW, Campbell C, Connolly AM, et al. Nusinersen versus sham control in later-onset spinal muscular atrophy. N Engl J Med. 2018;378(7):625\u201335. https:\/\/doi.org\/10.1056\/NEJMoa1710504.","journal-title":"N Engl J Med"},{"key":"1118_CR26","unstructured":"European Medicines Agency. Evrysdi summary of product characteristics. 2021. European Medicines Agency. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/evrysdi-epar-product-information_en.pdf. Accessed 07 Oct 2021."},{"key":"1118_CR27","unstructured":"ChoiceMetrics. Ngene 1.2 USER MANUAL & REFERENCE GUIDE The Cutting Edge in Experimental Design. 2018. http:\/\/www.choice-metrics.com\/NgeneManual120.pdf. Accessed 27 Apr 2021."},{"key":"1118_CR28","unstructured":"McFadden D (1973) Conditional logit analysis of qualitative choice behavior. In: Zarembka P (ed) Frontiers in econometrics. Academic Press, pp. 105\u2013142."},{"key":"1118_CR29","unstructured":"StataCorp. Stata Statistical Software: Release 16. College Station, TX: StataCorp LLC.; 2019. https:\/\/www.stata.com\/support\/faqs\/resources\/citing-software-documentation-faqs\/. Accessed 27 Apr 2021."}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-021-01118-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40273-021-01118-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-021-01118-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,9]],"date-time":"2022-04-09T15:19:15Z","timestamp":1649517555000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40273-021-01118-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,13]]},"references-count":29,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["1118"],"URL":"https:\/\/doi.org\/10.1007\/s40273-021-01118-2","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"value":"1170-7690","type":"print"},{"value":"1179-2027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,13]]},"assertion":[{"value":"21 November 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article is published in a special edition journal supplement wholly funded by F. Hoffmann-La Roche Ltd.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure statement"}},{"value":"This study was sponsored by F. Hoffmann-La Roche Ltd.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"SHL, CL and AJL are employees of Acaster Lloyd Consulting Ltd, who were commissioned by F. Hoffmann-La Roche Ltd to conduct this study. During the preparation of this manuscript, YM and AC were employed by F. Hoffmann-La Roche\u00a0Ltd.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest\/competing interests"}},{"value":"This study was reviewed and received exempt status determination by the Western Institutional Review Board (WIRB) on 19 August 2020 (submission number: 2639333-44664387). All participants gave informed consent prior to taking part in the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Freely given, informed consent to participate in the study was obtained from participants prior to participation in the study.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Freely given, informed consent to the scientific publication of the results of this research was obtained from participants prior to participation in the study.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The sponsor is adhering to current EU requirements, so will not make individual deidentified participant data available; however, the study protocol will be made available upon reasonable request to the corresponding author.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not available.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"SHL, CL and AJL designed the study. SHL analysed the data. SHL, CL and AJL interpreted the data and drafted the manuscript. YM and AC contributed to the design of the study, interpreted the data and revised the draft critically for important intellectual content. All authors approved the final version of the manuscript and agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.","order":10,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}